Morgan Stanley analyst Mark Purcell raised the firm’s price target on Novo Nordisk to DKK 800 from DKK 730 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/15/2024
- Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says
- Novo Nordisk price target raised to DKK 850 from DKK 775 at Deutsche Bank
- Novo Nordisk reports COMBINE 3 phase 3a trial achieved primary endpoint
- Tiziana Life files new patent application related to GLP-1ra, foralumab